Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.29 per share versus the Zacks Consensus Estimate of a loss of $1.2. This compares to a loss of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.32%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.23 per share when it actually produced a loss of $1.81, delivering a surprise of -47.15%.Over the last four quarters, the company h ...